Valneva SE (EPA:VLA)

Market Cap	487.40M
Revenue (ttm)	186.06M
Net Income (ttm)	-80.39M
Shares Out	167.15M
EPS (ttm)	-0.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,377,596
Average Volume	983,717
Open	2.760
Previous Close	2.830
Day's Range	2.696 - 2.968
52-Week Range	1.726 - 4.298
Beta	1.10
RSI	45.71
Earnings Date	May 7, 2025

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 713
• Stock Exchange: Euronext Paris
• Ticker Symbol: VLA

Financial Performance

In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.